Berend Olivier
Overview
Explore the profile of Berend Olivier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
220
Citations
3987
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Olivier B, Olivier J
Adv Exp Med Biol
. 2024 Sep;
1456:49-66.
PMID: 39261423
Major depressive disorder (MDD) is a highly prevalent psychiatric disorder, associated with substantial burden and large economical costs. Notwithstanding various conventional antidepressant treatment options, a large portion of depressed people...
2.
Olivier J, Janssen J, Esquivel-Franco D, de Pretre S, Olivier B
Front Neurosci
. 2023 Oct;
17:1224959.
PMID: 37781259
Lifelong premature ejaculation (PE) in men lacks an adequate on-demand pharmacological treatment. Although selective serotonin reuptake inhibitors (SSRIs) are used for PE they only work after chronic treatment, or if...
3.
Esquivel-Franco D, de Boer S, Waldinger M, Olivier B, Olivier J
Front Behav Neurosci
. 2020 Apr;
14:40.
PMID: 32296313
Brain serotonin (5-HT) neurotransmission plays an important role in male sexual behavior and it is well established that activating 5-HT receptors in rats facilitate ejaculatory behavior. However, the relative contribution...
4.
Gerritsen J, Bloemers J, van Rooij K, de Leede L, van der Geest R, Frijlink H, et al.
Sex Med
. 2020 Feb;
8(2):186-194.
PMID: 32088143
Introduction: A new combination tablet containing sublingual testosterone and oral buspirone (T+B) was developed to benefit a subgroup of women suffering from female sexual interest/arousal disorder, caused by dysfunctionally overactive...
5.
Olivier J, Olivier B
Adv Exp Med Biol
. 2020 Feb;
1191:121-140.
PMID: 32002926
Discovery of innovative anxiolytics is severely hampering. Existing anxiolytics are developed decades ago and are still the therapeutics of choice. Moreover, lack of new drug targets forecasts a severe jeopardy...
6.
Serefoglu E, Olivier B, Janssen P, de Pretre S, Snoeren E
Int J Impot Res
. 2019 Sep;
31(5):307-309.
PMID: 31519978
No abstract available.
7.
Bloemers J, Gerritsen J, van Rooij K, de Leede L, van der Geest R, Frijlink H, et al.
J Sex Med
. 2019 Sep;
16(9):1433-1443.
PMID: 31488289
Introduction: Female sexual interest/arousal disorder (FSIAD) affects many women worldwide, but pharmacological treatment options are scarce. A new medicine being developed for FSIAD is an on-demand, dual-route, dual-release drug combination...
8.
Tuiten A, Michiels F, Bocker K, Hohle D, van Honk J, de Lange R, et al.
Womens Health (Lond)
. 2018 Jul;
14:1745506518788970.
PMID: 30016917
Attempts to develop a drug treatment for female sexual interest/arousal disorder have so far been guided by the principle of 'one size fits all', and have failed to acknowledge the...
9.
Esquivel-Franco D, Olivier B, Waldinger M, Gutierrez-Ospina G, Olivier J
Front Pharmacol
. 2018 Jul;
9:676.
PMID: 29997507
Tramadol is an effective pharmacological intervention in human premature ejaculation (PE). To investigate whether the inhibitory action of tramadol is primarily caused by its selective serotonin reuptake inhibitory (SSRI) effects...
10.
Tuiten A, van Rooij K, Bloemers J, Eisenegger C, van Honk J, Kessels R, et al.
J Sex Med
. 2018 Jan;
15(2):201-216.
PMID: 29289554
Background: In women, low sexual desire and/or sexual arousal can lead to sexual dissatisfaction and emotional distress, collectively defined as female sexual interest/arousal disorder (FSIAD). Few pharmaceutical treatment options are...